[go: up one dir, main page]

SE9303281D0 - New formulation - Google Patents

New formulation

Info

Publication number
SE9303281D0
SE9303281D0 SE9303281A SE9303281A SE9303281D0 SE 9303281 D0 SE9303281 D0 SE 9303281D0 SE 9303281 A SE9303281 A SE 9303281A SE 9303281 A SE9303281 A SE 9303281A SE 9303281 D0 SE9303281 D0 SE 9303281D0
Authority
SE
Sweden
Prior art keywords
pct
formulation
sec
optionally
date
Prior art date
Application number
SE9303281A
Other languages
English (en)
Swedish (sv)
Inventor
Stefan Lundquist
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9303281A priority Critical patent/SE9303281D0/xx
Publication of SE9303281D0 publication Critical patent/SE9303281D0/xx
Priority to IS4209A priority patent/IS4209A/is
Priority to ZA947351A priority patent/ZA947351B/xx
Priority to IL11113194A priority patent/IL111131A/xx
Priority to AU78667/94A priority patent/AU701512B2/en
Priority to SK393-96A priority patent/SK39396A3/sk
Priority to CN94194055A priority patent/CN1134663A/zh
Priority to DE69422818T priority patent/DE69422818T2/de
Priority to NZ274583A priority patent/NZ274583A/en
Priority to CA002172143A priority patent/CA2172143A1/en
Priority to AT94929711T priority patent/ATE189119T1/de
Priority to EG62594A priority patent/EG20540A/xx
Priority to SG1996005087A priority patent/SG47896A1/en
Priority to DK94929711T priority patent/DK0722316T3/da
Priority to EP94929711A priority patent/EP0722316B1/en
Priority to BR9407748A priority patent/BR9407748A/pt
Priority to CZ96943A priority patent/CZ94396A3/cs
Priority to HU9600900A priority patent/HUT74638A/hu
Priority to US08/379,486 priority patent/US5843465A/en
Priority to PT94929711T priority patent/PT722316E/pt
Priority to ES94929711T priority patent/ES2145158T3/es
Priority to HK98109962.8A priority patent/HK1009257B/en
Priority to FI961525A priority patent/FI961525L/fi
Priority to PL94313767A priority patent/PL313767A1/xx
Priority to JP7510759A priority patent/JPH09504279A/ja
Priority to PCT/SE1994/000926 priority patent/WO1995009609A1/en
Priority to MA23666A priority patent/MA23344A1/fr
Priority to TNTNSN94099A priority patent/TNSN94099A1/fr
Priority to EE9400426A priority patent/EE03235B1/xx
Priority to US08/460,046 priority patent/US5660837A/en
Priority to NO961363A priority patent/NO961363D0/no
Priority to GR20000400938T priority patent/GR3033255T3/el

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9303281A 1993-10-07 1993-10-07 New formulation SE9303281D0 (sv)

Priority Applications (32)

Application Number Priority Date Filing Date Title
SE9303281A SE9303281D0 (sv) 1993-10-07 1993-10-07 New formulation
IS4209A IS4209A (is) 1993-10-07 1994-09-21 Lyfjablanda sem inniheldur í miklu magni lyf sem er yfirborðsvirkt efni sem eykur stöðugleika dropalausna og aðferð við að framleiða hana
ZA947351A ZA947351B (en) 1993-10-07 1994-09-21 New emulsion formulation.
IL11113194A IL111131A (en) 1993-10-07 1994-10-03 Emulsion formulation
PCT/SE1994/000926 WO1995009609A1 (en) 1993-10-07 1994-10-05 New emulsion formulation
EP94929711A EP0722316B1 (en) 1993-10-07 1994-10-05 New emulsion formulation
HU9600900A HUT74638A (en) 1993-10-07 1994-10-05 New emulsion formulation
CN94194055A CN1134663A (zh) 1993-10-07 1994-10-05 新的乳剂
DE69422818T DE69422818T2 (de) 1993-10-07 1994-10-05 Neue emulsionsformulierung
NZ274583A NZ274583A (en) 1993-10-07 1994-10-05 Pharmaceutical oil-in-water emulsion with a surface active drug in high concentration
CA002172143A CA2172143A1 (en) 1993-10-07 1994-10-05 New emulsion formulation
AT94929711T ATE189119T1 (de) 1993-10-07 1994-10-05 Neue emulsionsformulierung
EG62594A EG20540A (en) 1993-10-07 1994-10-05 New emulsion formulation
SG1996005087A SG47896A1 (en) 1993-10-07 1994-10-05 New emulsion formulation
DK94929711T DK0722316T3 (da) 1993-10-07 1994-10-05 Nyt emulsionspræparat
AU78667/94A AU701512B2 (en) 1993-10-07 1994-10-05 New emulsion formulation
BR9407748A BR9407748A (pt) 1993-10-07 1994-10-05 Formulação farmacéutica processo para preparação da mesma e processo para a prevenção e/ou o tratamento de neurodegeneração ou para a obtenção de um efeito anti-convulsivo ou sedação em um paciente
CZ96943A CZ94396A3 (en) 1993-10-07 1994-10-05 Novel emulsion preparation
SK393-96A SK39396A3 (en) 1993-10-07 1994-10-05 Emulsion agent
US08/379,486 US5843465A (en) 1993-10-07 1994-10-05 Emulsion formulation
PT94929711T PT722316E (pt) 1993-10-07 1994-10-05 Nova formulacao de emulsao
ES94929711T ES2145158T3 (es) 1993-10-07 1994-10-05 Nueva formulacion de emulsion.
HK98109962.8A HK1009257B (en) 1993-10-07 1994-10-05 New emulsion formulation
FI961525A FI961525L (fi) 1993-10-07 1994-10-05 Uusi emulsioformulaatio
PL94313767A PL313767A1 (en) 1993-10-07 1994-10-05 Novel emulsion preparation
JP7510759A JPH09504279A (ja) 1993-10-07 1994-10-05 新エマルジョン製剤
MA23666A MA23344A1 (fr) 1993-10-07 1994-10-06 Nouvelles compositions d'emulsions
TNTNSN94099A TNSN94099A1 (fr) 1993-10-07 1994-10-07 Nouvelles compositions d'emulsions
EE9400426A EE03235B1 (et) 1993-10-07 1994-11-23 Emulsioonvorm, selle valmistamise protsess ja kasutamine
US08/460,046 US5660837A (en) 1993-10-07 1995-06-02 Preparing pharmaceutical formulation in form of oil-in-water emulsion
NO961363A NO961363D0 (no) 1993-10-07 1996-04-02 Nytt emulsjonspreparat
GR20000400938T GR3033255T3 (en) 1993-10-07 2000-04-17 New emulsion formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9303281A SE9303281D0 (sv) 1993-10-07 1993-10-07 New formulation

Publications (1)

Publication Number Publication Date
SE9303281D0 true SE9303281D0 (sv) 1993-10-07

Family

ID=20391342

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9303281A SE9303281D0 (sv) 1993-10-07 1993-10-07 New formulation

Country Status (30)

Country Link
US (2) US5843465A (xx)
EP (1) EP0722316B1 (xx)
JP (1) JPH09504279A (xx)
CN (1) CN1134663A (xx)
AT (1) ATE189119T1 (xx)
AU (1) AU701512B2 (xx)
BR (1) BR9407748A (xx)
CA (1) CA2172143A1 (xx)
CZ (1) CZ94396A3 (xx)
DE (1) DE69422818T2 (xx)
DK (1) DK0722316T3 (xx)
EE (1) EE03235B1 (xx)
EG (1) EG20540A (xx)
ES (1) ES2145158T3 (xx)
FI (1) FI961525L (xx)
GR (1) GR3033255T3 (xx)
HU (1) HUT74638A (xx)
IL (1) IL111131A (xx)
IS (1) IS4209A (xx)
MA (1) MA23344A1 (xx)
NO (1) NO961363D0 (xx)
NZ (1) NZ274583A (xx)
PL (1) PL313767A1 (xx)
PT (1) PT722316E (xx)
SE (1) SE9303281D0 (xx)
SG (1) SG47896A1 (xx)
SK (1) SK39396A3 (xx)
TN (1) TNSN94099A1 (xx)
WO (1) WO1995009609A1 (xx)
ZA (1) ZA947351B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
US6054421A (en) * 1997-09-23 2000-04-25 Scimed Life Systems, Inc. Medical emulsion lubricant
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
ATE252889T1 (de) 1998-08-19 2003-11-15 Skyepharma Canada Inc Injizierbare wässerige propofoldispersionen
US20100184732A1 (en) * 2000-09-15 2010-07-22 Mcdonald George Method of long-term treatment of graft-versus-host disease using topical active corticosteroids
US20020086857A1 (en) * 2000-09-15 2002-07-04 Mcdonald George B. Method of long-term treatment of graft-versus-host disease using topical active corticosterioids
DE10059430A1 (de) * 2000-11-30 2002-06-06 Cognis Deutschland Gmbh Feinteilige Emulsionen
CA2449856C (en) 2001-06-15 2009-03-10 Cornerstone Pharmaceuticals Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
PT1416917E (pt) * 2001-08-06 2007-08-16 Astrazeneca Ab ''dispersão aquosa compreendendo nanopartículas estáveis de um triglicérido de cadeia média (mct) activo insolúvel em água e um do tipo excipiente''
TWI248159B (en) * 2002-01-25 2006-01-21 Nanya Technology Corp Manufacturing method for shallow trench isolation with high aspect ratio
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
US7544674B2 (en) * 2002-10-25 2009-06-09 Galderma S.A. Topical skin care composition
US8685428B2 (en) * 2002-12-10 2014-04-01 Advanced Cardiovascular Systems, Inc. Therapeutic composition and a method of coating implantable medical devices
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7323206B1 (en) 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2004111033A1 (en) * 2003-06-18 2004-12-23 Astrazeneca Ab 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2005009406A1 (en) * 2003-07-18 2005-02-03 Hill Dermaceuticals, Inc. Topical skin care composition containing refined peanut oil
US20070140999A1 (en) * 2003-07-18 2007-06-21 Hill Dermaceuticals, Inc. Topical skin care composition containing refined peanut oil
US20060099173A1 (en) * 2003-10-24 2006-05-11 Nancy Puglia Topical skin care composition
US20070207107A1 (en) * 2006-03-03 2007-09-06 Gareth Winckle Silicone based emulsions for topical drug delivery
US8473062B2 (en) 2008-05-01 2013-06-25 Autonomic Technologies, Inc. Method and device for the treatment of headache
US8412336B2 (en) 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US9320908B2 (en) 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
US8494641B2 (en) 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4073943A (en) * 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
AT358530B (de) * 1978-04-25 1980-09-10 Plc Pharma Licences Stabilisierungsverfahren
JPS58222014A (ja) * 1982-06-18 1983-12-23 Taisho Pharmaceut Co Ltd プロスタグランジンｅ↓１脂肪乳剤
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
JPH0818989B2 (ja) * 1984-01-12 1996-02-28 株式会社ミドリ十字 脂肪乳剤中のプロスタグランジンの安定化方法
JPH0647533B2 (ja) * 1984-08-10 1994-06-22 裕 水島 ４−ビフエニリル酢酸系化合物含有脂肪乳剤
US4760096A (en) * 1985-09-27 1988-07-26 Schering Corporation Moisturizing skin preparation
DE3623376A1 (de) * 1986-07-11 1988-01-21 Behringwerke Ag Pharmazeutische formulierung und verfahren zu deren herstellung
GB8919172D0 (en) * 1989-08-23 1989-10-04 Univ Nottingham Useful composition
JP2785981B2 (ja) * 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
US5089268A (en) * 1990-05-02 1992-02-18 Katz David P Egg phosphatide lipid emulsions altered for a specific therapeutic fatty acid composition

Also Published As

Publication number Publication date
AU7866794A (en) 1995-05-01
PL313767A1 (en) 1996-07-22
FI961525A7 (fi) 1996-04-04
NO961363L (no) 1996-04-02
EP0722316A1 (en) 1996-07-24
HK1009257A1 (en) 1999-05-28
EG20540A (en) 1999-07-31
PT722316E (pt) 2000-06-30
FI961525A0 (fi) 1996-04-04
CA2172143A1 (en) 1995-04-13
CN1134663A (zh) 1996-10-30
US5660837A (en) 1997-08-26
BR9407748A (pt) 1997-11-11
DK0722316T3 (da) 2000-06-13
NO961363D0 (no) 1996-04-02
US5843465A (en) 1998-12-01
SK39396A3 (en) 1997-02-05
MA23344A1 (fr) 1995-07-01
IL111131A0 (en) 1994-12-29
SG47896A1 (en) 1998-04-17
HU9600900D0 (en) 1996-05-28
GR3033255T3 (en) 2000-09-29
FI961525L (fi) 1996-04-04
EP0722316B1 (en) 2000-01-26
ATE189119T1 (de) 2000-02-15
ES2145158T3 (es) 2000-07-01
IS4209A (is) 1995-04-08
WO1995009609A1 (en) 1995-04-13
DE69422818T2 (de) 2000-07-27
EE03235B1 (et) 1999-12-15
DE69422818D1 (de) 2000-03-02
HUT74638A (en) 1997-01-28
NZ274583A (en) 1998-01-26
AU701512B2 (en) 1999-01-28
IL111131A (en) 1999-09-22
ZA947351B (en) 1995-04-10
TNSN94099A1 (fr) 1995-04-25
JPH09504279A (ja) 1997-04-28
CZ94396A3 (en) 1996-06-12

Similar Documents

Publication Publication Date Title
SE9303281D0 (sv) New formulation
SE9503143D0 (sv) New preparation
ATE213940T1 (de) Parenteral anzuwendende arzneizubereitung enthaltend amiodaron
ATE213158T1 (de) Pharmazeutische emulsion
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
SE9502219D0 (sv) Novel medical use
SE9402880D0 (sv) New peptide derivatives
PT706395E (pt) Uso de ropivacaina na preparacao duma composicao farmaceutica com efeito analgesico e bloqueio motor minimo
ATE221068T1 (de) Anellierte beta-carboline